Either of these possibilities is consistent with clinical observations that PTHrP-positivity in breast cancer is greater in BMET than in other metastatic sites or in primary tumors[62], a finding also verified in pre-clinical murine studies documenting greater PTHrP expression in human breast cancer cells spontaneously forming metastases in bone vs. other sites[73]. This evidence concerns the gene PTHLH and breast cancer.